Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seasonal asthma exacerbation prevention with depemokimab
ISRCTN11308300Phase 3Completed
- Sponsor
- King's College London
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in asthma comparing Depemokimab plus standard of care with Placebo plus standard of care (2 arms). Primary endpoint: Asthma exacerbations annualised rate. Started Aug 2025; status: completed.
02
Drugs
depemokimab
03
Conditions
asthma
Beyond the preview
Go deeper on ISRCTN11308300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN11308300.